ALZAMEND NEURO, INC. Deferred Tax Assets, Valuation Allowance
ALZAMEND NEURO, INC. (ALZN) had Deferred Tax Assets, Valuation Allowance of $15.40 million as of 2026-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-07-22
- 2026-04-30: Deferred Tax Assets, Valuation Allowance $15.40M.
- 2025-04-30: Deferred Tax Assets, Valuation Allowance $15.25M.
- 2024-04-30: Deferred Tax Assets, Valuation Allowance $15.77M.
- 2023-04-30: Deferred Tax Assets, Valuation Allowance $10.81M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2026-04-30 | $15.40M 10-K · filed 2026-07-22 |
| 2025-04-30 | $15.25M 10-K · filed 2026-07-22 |
| 2024-04-30 | $15.77M 10-K · filed 2025-07-22 |
| 2023-04-30 | $10.81M 10-K · filed 2024-07-30 |
| 2022-04-30 | $10.08M 10-K · filed 2023-07-27 |
| 2021-04-30 | $4.35M 10-K · filed 2022-07-19 |
| 2020-04-30 | $2.84M 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |